-
.treatment delays are also causing needless anxiety and distress to patients as well as putting lives at serious risk (file pic)
.
.
.
erenumab (aimovig) is the first of four new migraine drugs in the pipeline that target calcitonin gene-related peptide (cgrp), a molecule that's produced in nerve cells of the
OFF DEAL
218 Used Today
OFF DEAL
181 Used Today